Literature DB >> 15098810

Tacrolimus toxicity associated with concomitant metoclopramide therapy.

William A Prescott1, Brian L Callahan, Jeong M Park.   

Abstract

Subtherapeutic tacrolimus trough concentrations were noted in a 52-year-old woman who had undergone liver transplantation. Her tacrolimus dosage was increased from 7 to 28 mg twice/day, and ketoconazole therapy was added; however, her tacrolimus concentration remained undetectable. Metoclopramide 10 mg 4 times/day was begun to control the patient's new-onset nausea and vomiting. Within 48 hours of increasing the dosage to 20 mg 4 times/day, her tacrolimus trough concentration exceeded 30 ng/ml. Signs and symptoms were suggestive of tacrolimus nephrotoxicity and neurotoxicity. According to the Naranjo scale, this adverse drug event was probably the result of improved absorption of tacrolimus secondary to metoclopramide therapy. The patient's subtherapeutic tacrolimus concentration at baseline was probably secondary to poor absorption due to impaired gastric emptying. Coadministration of metoclopramide significantly improved gastric motility and delivery of tacrolimus to the small intestine, increasing tacrolimus bioavailability, thus resulting in acute-onset tacrolimus toxicity. When tacrolimus is administered with metoclopramide in patients with gastric dysmotility, tacrolimus concentrations should be monitored closely to minimize the risk of toxicity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15098810     DOI: 10.1592/phco.24.5.532.33357

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  2 in total

1.  Tacrolimus induced leukoencephalopathy presenting with status epilepticus and prolonged coma.

Authors:  Mithri R Junna; Alejandro A Rabinstein
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-12       Impact factor: 10.154

2.  MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia.

Authors:  Dong Xu; Alexandrea G Ham; Rickey D Tivis; Matthew L Caylor; Aoxiang Tao; Steve T Flynn; Peter J Economen; Hung K Dang; Royal W Johnson; Vaughn L Culbertson
Journal:  EBioMedicine       Date:  2017-11-22       Impact factor: 8.143

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.